EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Associations of Commonly Used Concomitant Medications With Survival and Adverse Event Outcomes in Breast Cancer

Natansh D Modi, Ahmad Y Abuhelwa, Nicole M Kuderer, Lee X Li, Gary H Lyman, Bogda Koczwara iD, Ganessan Kichenadasse, Luke A Selth, Ceara Rickard, Mark Haseloff, Agnes Vitry, Richard Woodman und 7 weitere

Cancer Medicine · 2025

DOI: 10.1002/cam4.71320 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Natansh D Modi und 18 weiteren Autor:innen. Beteiligte Einrichtung: Flinders University, College of Medicine and Public Health, Flinders Health and Medical Research Institute, Adelaide, Australia. Hauptthemen laut MEDLINE: Breast Neoplasms, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Prostate Cancer Foundation of Australia, Tour de Cure, National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The impact of commonly used non‐cancer medications on breast cancer outcomes remains underexplored in large datasets.

Aims

To evaluate the associations between commonly used non‐cancer medications and survival as well as adverse events in patients with breast cancer. Materials & Methods Individual participant data from 19 breast cancer clinical trials ( n = 23,211) were pooled. Cox proportional hazards models and logistic regression analyses were used to assess associations between medication use and overall survival, progression‐free survival and grade ≥ 3 adverse events. Analyses were adjusted for demographic, cancer and comorbidity factors.

Results

Proton pump inhibitor use was associated with poorer overall survival (HR 1.19, 95% CI: 1.08–1.30), progression‐free survival (HR 1.11, 95% CI: 1.02–1.21) and an increased risk of grade ≥ 3 adverse events (OR 1.36, 95% CI: 1.21–1.53). Beta‐blockers, ACE inhibitors/ARBs and calcium channel blockers were linked with higher adverse event rates but showed no significant impact on survival. Statins and metformin demonstrated no significant associations with either survival or adverse events.

Conclusion

These findings emphasise the need for careful management of concomitant medications in breast cancer care and support ongoing research to optimise treatment safety and efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsDrug-Related Side Effects and Adverse ReactionsHumansFemaleMiddle AgedAgedProton Pump InhibitorsAdultProportional Hazards ModelsCalcium Channel BlockersAngiotensin-Converting Enzyme InhibitorsAdrenergic beta-AntagonistsHydroxymethylglutaryl-CoA Reductase InhibitorsProgression-Free Survival

Stichwörter der Autor:innen

adverse eventsbreast cancercardiovascular drugsconcomitant medicationsindividual participant data meta‐analysisproton pump inhibitorssurvival outcomes

Substanzen

Proton Pump InhibitorsCalcium Channel BlockersAngiotensin-Converting Enzyme InhibitorsAdrenergic beta-AntagonistsHydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • Flinders University, College of Medicine and Public Health, Flinders Health and Medical Research Institute, Adelaide, Australia.
  • Clinical and Health Sciences, University of South Australia, Adelaide, Australia.
  • Department of Pharmacy Practice and Pharmacotherapeutics, College of Pharmacy, University of Sharjah, Sharjah, UAE.
  • Advanced Cancer Research Group, Kirkland, Washington, USA.
  • Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA.
  • Flinders Centre for Innovation in Cancer, Department of Medical Oncology, Flinders Medical Centre, Flinders University, Adelaide, Australia.

ORCID-Profile: Bogda Koczwara, Huah Shin Ng

Förderung

  • Prostate Cancer Foundation of Australia
  • Tour de Cure
  • National Health and Medical Research Council
  • Hospital Research Foundation
  • Cancer Council Australia
  • Flinders Foundation
  • University of Sharjah
  • Cancer Council South Australia

Zitieren

APA

Modi, N. D., Abuhelwa, A. Y., Kuderer, N. M., Li, L. X., Lyman, G. H., Koczwara, B., Kichenadasse, G., Selth, L. A., Rickard, C., Haseloff, M., Vitry, A., Woodman, R., Logan, J. M., Ng, H. S., Wiese, M. D., McKinnon, R. A., Rowland, A., Sorich, M. J., & Hopkins, A. M. (2025). Associations of Commonly Used Concomitant Medications With Survival and Adverse Event Outcomes in Breast Cancer. Cancer Medicine. https://doi.org/10.1002/cam4.71320

Vancouver

Modi ND, Abuhelwa AY, Kuderer NM, Li LX, Lyman GH, Koczwara B, et al. Associations of Commonly Used Concomitant Medications With Survival and Adverse Event Outcomes in Breast Cancer. Cancer Medicine. 2025. doi:10.1002/cam4.71320

BibTeX
@article{Modi2025,
  author = {Modi, Natansh D and Abuhelwa, Ahmad Y and Kuderer, Nicole M and Li, Lee X and Lyman, Gary H and Koczwara, Bogda and Kichenadasse, Ganessan and Selth, Luke A and Rickard, Ceara and Haseloff, Mark and Vitry, Agnes and Woodman, Richard and Logan, Jessica M and Ng, Huah Shin and Wiese, Michael D and McKinnon, Ross A and Rowland, Andrew and Sorich, Michael J and Hopkins, Ashley M},
  title = {Associations of Commonly Used Concomitant Medications With Survival and Adverse Event Outcomes in Breast Cancer},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.71320}
}
Kostenlos starten →